Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Current Deferred Revenue (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Current Deferred Revenue for 3 consecutive years, with $502000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $502000.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $502000.0, a N/A change, with the full-year FY2023 number at $1.3 million, down 82.51% from a year prior.
  • Current Deferred Revenue was $502000.0 for Q1 2024 at Werewolf Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.7 million in Q4 2022 to a low of $502000.0 in Q1 2024.
  • A 3-year average of $2.9 million and a median of $2.4 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 82.51% in 2023; the steepest drop was 82.51% in 2023.
  • Werewolf Therapeutics' Current Deferred Revenue stood at $7.7 million in 2022, then tumbled by 82.51% to $1.3 million in 2023, then plummeted by 62.54% to $502000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Current Deferred Revenue are $502000.0 (Q1 2024), $1.3 million (Q4 2023), and $2.4 million (Q3 2023).